DIVISLAB — Divi's Laboratories Share Price
0.000.00%
Last trade - 00:00- IN₹1.49tn
- IN₹1.46tn
- IN₹78.45bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 56.84 | ||
| PEG Ratio (f) | 2.83 | ||
| EPS Growth (f) | 25.17% | ||
| Dividend Yield (f) | 0.55% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.88 | ||
| Price to Tang. Book | 10.88 | ||
| Price to Free Cashflow | 314.12 | ||
| Price to Sales | 16.44 | ||
| EV to EBITDA | 51.74 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 16.96% | ||
| Return on Equity | 15.66% | ||
| Operating Margin | 26.7% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 53,944.2 | 69,694 | 89,598.3 | 77,675.1 | 78,450 | 93,127.56 | 108,453.25 | 9.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +1.86 | +44.22 | +48.94 | -38.41 | -12.13 | +32.25 | +24.92 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, Vigabatrin, and others. The Company is also engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG.
Directors
- Ramesh Nimmagadda NEC
- Kiran Divi CEO (44)
- L. Kishore Babu CFO (71)
- M. Satish Choudhury CCO
- Murali Divi MDR (70)
- Madhusudana Divi EDR (77)
- N. Ramana EDR (63)
- K. V. Chowdary NID
- S. Ganapaty NID (67)
- G. Suresh Kumar NID
- Ravipati Rao NID
- Kantheti Seshavataram NID
- Sunaina Singh NID (64)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 12th, 1990
- Public Since
- June 25th, 1905
- No. of Shareholders
- 347,630
- No. of Employees
- 17,500
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 265,468,580
- Address
- 1-72/23(P)/Divis/303, HYDERABAD, 500032
- Web
- https://www.divislabs.com/
- Phone
- +91 4023786300
- Contact
- Meka Satish Choudhury
- Auditors
- Price Waterhouse Chartered Accountants LLP
Upcoming Events for DIVISLAB
Q1 2026 Divi's Laboratories Ltd Earnings Release
Similar to DIVISLAB
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Divi's Laboratories share price?
As of Today at 01:16 UTC, shares in Divi's Laboratories are trading at IN₹5,620.45. This share price information is delayed by 15 minutes.
How has the Divi's Laboratories share price performed this year?
Shares in Divi's Laboratories last closed at IN₹5,620.45 and the price had moved by +61.52% over the past 365 days. In terms of relative price strength the Divi's Laboratories share price has outperformed the S&P BSE 100 Index by +59.18% over the past year.
What are the analyst and broker recommendations for Divi's Laboratories?
The overall consensus recommendation for Divi's Laboratories is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Divi's Laboratories dividend yield?
The Divi's Laboratories dividend yield is 0.53% based on the trailing twelve month period.
Does Divi's Laboratories pay a dividend?
Last year, Divi's Laboratories paid a total dividend of IN₹30.00, and it currently has a trailing dividend yield of 0.53%. We do not have any data on when Divi's Laboratories is to next pay dividends.
When does Divi's Laboratories next pay dividends?
We do not have data on when Divi's Laboratories is to next pay dividends. The historic dividend yield on Divi's Laboratories shares is currently 0.53%.
How do I buy Divi's Laboratories shares?
To buy shares in Divi's Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Divi's Laboratories?
As of the previous close price of IN₹5,620.45, shares in Divi's Laboratories had a market capitalisation of IN₹1.49tn.
Where are Divi's Laboratories shares listed?
Here are the trading details for Divi's Laboratories:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: DIVISLAB
What kind of share is Divi's Laboratories?
Based on an overall assessment of its quality, value and momentum Divi's Laboratories is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Divi's Laboratories share price forecast for 2025?
The analyst consensus target price for shares in Divi's Laboratories is IN₹5,543.75. That is 1.36% below the last closing price of IN₹5,620.45.
Analysts covering Divi's Laboratories currently have a consensus Earnings Per Share (EPS) forecast of IN₹79.86 for the next financial year.
Find out moreWhat is the trend in the Divi's Laboratories share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Divi's Laboratories. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +17.85%.
As of the last closing price of IN₹5,620.45, shares in Divi's Laboratories were trading +3.8% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Divi's Laboratories PE Ratio?
The Divi's Laboratories PE ratio based on its reported earnings over the past 12 months is 56.84. The shares last closed at IN₹5,620.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Divi's Laboratories?
Divi's Laboratories' management team is headed by:
- Ramesh Nimmagadda - NEC
- Kiran Divi - CEO
- L. Kishore Babu - CFO
- M. Satish Choudhury - CCO
- Murali Divi - MDR
- Madhusudana Divi - EDR
- N. Ramana - EDR
- K. V. Chowdary - NID
- S. Ganapaty - NID
- G. Suresh Kumar - NID
- Ravipati Rao - NID
- Kantheti Seshavataram - NID
- Sunaina Singh - NID